Vaccinex, Inc. (VCNX)
OTCMKTS
· Delayed Price · Currency is USD
0.7500
+0.1700 (29.31%)
Jun 30, 2025, 12:31 PM EDT
Vaccinex Revenue
In the year 2024, Vaccinex had annual revenue of $601.00K with 5.44% growth. Vaccinex had revenue of $213.00K in the quarter ending December 31, 2024.
Revenue
601.00K
Revenue Growth
+5.44%
P/S Ratio
3.25
Revenue / Employee
24.04K
Employees
27
Market Cap
1.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 601.00K | 31.00K | 5.44% |
| Dec 31, 2023 | 570.00K | 295.00K | 107.27% |
| Dec 31, 2022 | 275.00K | -625.00K | -69.44% |
| Dec 31, 2021 | 900.00K | 275.00K | 44.00% |
| Dec 31, 2020 | 625.00K | 102.00K | 19.50% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 70.00M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 215.62M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
Vaccinex News
- 5 weeks ago - Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting - GlobeNewsWire
- 2 months ago - Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) - GlobeNewsWire
- 4 months ago - Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - GlobeNewsWire
- 4 months ago - ARMISTICE CAPITAL, LLC Reduces Stake in Vaccinex Inc: A Strategic Portfolio Adjustment - GuruFocus
- 7 months ago - Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock? - Benzinga
- 8 months ago - Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 months ago - Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC - GlobeNewsWire
- 8 months ago - Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting - GlobeNewsWire